Open Access

Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma

  • Authors:
    • Aram A. Musaelyan
    • Sergey V. Lapin
    • Margarita A. Urtenova
    • Svetlana V. Odintsova
    • Ivan V. Chistyakov
    • Andrey M. Ulitin
    • Andrey L. Akopov
    • Sergey V. Orlov
  • View Affiliations

  • Published online on: July 5, 2022     https://doi.org/10.3892/etm.2022.11495
  • Article Number: 557
  • Copyright: © Musaelyan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Immune checkpoint inhibitors (ICI) are a standard in cancer therapy, but few patients respond to the treatment. The aim of the present study was the determination of immunological markers for monitoring response to ICI. The present study included 74 patients receiving ICI in subsequent [group 1; non‑small cell lung cancer (NSCLC)] and first‑line setting (group 2; melanoma) and 30 patients with NSCLC receiving first‑line chemotherapy. In groups 1 and 2 β‑2 microglobulin (B2‑MG), neopterin (NPT), IL‑6, IL‑18, HLA‑DRB1 and autoantibodies were assessed after two months of ICI, and before the start of next administration in group 3. In group 1 low level of B2‑MG (P<0.0001), NPT (P<0.0001), IL‑6 (P<0.0001), IL‑18 (P=0.0003), HLA‑DRB1*03 (P=0.016) and anti‑TPO antibodies (P=0.016) were associated with response >six months. In group 2 high level of B2‑MG (P=0.0001), NPT (P=0.0016), IL‑6 (P=0.013) and IL‑18 (P=0.032) were associated with early disease progression (<six months). Univariate analysis demonstrated that immune‑related adverse events were predictive marker of prolonged progression‑free survival (PFS) in group 1 (P=0.038) and 2 (P=0.020). Neutrophil‑lymphocyte ratio ≥5 before immunotherapy was correlated with shorter PFS in melanoma in multivariate analysis (P=0.007). B2‑MG ≥2.5 mg/ml (P=0.006) and NPT ≥12 nmol/l (P=0.027) were predictors of shorter PFS in group 1. B2‑MG ≥2.5 mg/ml was predictor of shorter PFS (P=0.008) in group 2. In group 1 levels of B2‑MG, NPT, IL‑6 and IL‑18 were higher than in group 3. In summary, immunological markers are promising predictive markers for immunotherapy; however, it requires further prospective studies.

Related Articles

Journal Cover

September-2022
Volume 24 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Musaelyan AA, Lapin SV, Urtenova MA, Odintsova SV, Chistyakov IV, Ulitin AM, Akopov AL and Orlov SV: Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma. Exp Ther Med 24: 557, 2022
APA
Musaelyan, A.A., Lapin, S.V., Urtenova, M.A., Odintsova, S.V., Chistyakov, I.V., Ulitin, A.M. ... Orlov, S.V. (2022). Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma. Experimental and Therapeutic Medicine, 24, 557. https://doi.org/10.3892/etm.2022.11495
MLA
Musaelyan, A. A., Lapin, S. V., Urtenova, M. A., Odintsova, S. V., Chistyakov, I. V., Ulitin, A. M., Akopov, A. L., Orlov, S. V."Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma". Experimental and Therapeutic Medicine 24.3 (2022): 557.
Chicago
Musaelyan, A. A., Lapin, S. V., Urtenova, M. A., Odintsova, S. V., Chistyakov, I. V., Ulitin, A. M., Akopov, A. L., Orlov, S. V."Inflammatory and autoimmune predictive markers of response to anti‑PD‑1/PD‑L1 therapy in NSCLC and melanoma". Experimental and Therapeutic Medicine 24, no. 3 (2022): 557. https://doi.org/10.3892/etm.2022.11495